Renaissance Technologies LLC Has $1.66 Million Stock Holdings in Alumis Inc. $ALMS

Renaissance Technologies LLC trimmed its position in Alumis Inc. (NASDAQ:ALMS) by 30.5% during the first quarter, according to the company in its most recent 13F filing with the SEC. The firm owned 75,167 shares of the company’s stock after selling 33,033 shares during the quarter. Renaissance Technologies LLC owned approximately 0.06% of Alumis worth $1,656,000 as of its most recent SEC filing.

Several other hedge funds have also bought and sold shares of the company. KBC Group NV acquired a new position in Alumis during the first quarter worth approximately $42,000. Strs Ohio raised its stake in Alumis by 300.0% in the first quarter. Strs Ohio now owns 2,000 shares of the company’s stock valued at $44,000 after buying an additional 1,500 shares during the period. State of Wyoming acquired a new stake in shares of Alumis in the first quarter valued at approximately $57,000. Assetmark Inc. acquired a new stake in shares of Alumis in the first quarter valued at approximately $92,000. Finally, Mirae Asset Global Investments Co. Ltd. lifted its position in shares of Alumis by 26.1% in the fourth quarter. Mirae Asset Global Investments Co. Ltd. now owns 4,724 shares of the company’s stock valued at $46,000 after buying an additional 979 shares during the last quarter.

Insider Transactions at Alumis

In other Alumis news, insider Mark Christopher Bradley sold 2,572 shares of the stock in a transaction on Monday, August 3rd. The stock was sold at an average price of $26.37, for a total transaction of $67,823.64. Following the transaction, the insider owned 48,533 shares in the company, valued at $1,279,815.21. This trade represents a 5.03% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, insider David M. Goldstein sold 2,596 shares of Alumis stock in a transaction on Monday, August 3rd. The stock was sold at an average price of $26.37, for a total value of $68,456.52. Following the sale, the insider directly owned 30,970 shares of the company’s stock, valued at $816,678.90. This represents a 7.73% decrease in their position. The SEC filing for this sale provides additional information. Over the last quarter, insiders sold 19,953 shares of company stock worth $534,311. 33.70% of the stock is currently owned by company insiders.

Alumis Stock Down 7.8%

Shares of NASDAQ:ALMS opened at $25.37 on Wednesday. Alumis Inc. has a 12-month low of $3.76 and a 12-month high of $31.35. The business has a 50 day moving average of $25.87 and a 200-day moving average of $25.28. The stock has a market cap of $3.23 billion, a PE ratio of -12.81 and a beta of -0.69.

Alumis (NASDAQ:ALMS) last announced its earnings results on Thursday, May 14th. The company reported ($0.74) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.73) by ($0.01). The firm had revenue of $1.74 million for the quarter, compared to the consensus estimate of $2.10 million. Alumis had a negative return on equity of 88.79% and a negative net margin of 2,825.70%. Equities research analysts expect that Alumis Inc. will post -2.87 earnings per share for the current year.

Analyst Ratings Changes

A number of research analysts recently weighed in on the company. Weiss Ratings reissued a “sell (d-)” rating on shares of Alumis in a report on Tuesday, July 7th. HC Wainwright reaffirmed a “neutral” rating and set a $25.00 price target on shares of Alumis in a report on Monday, August 3rd. Wells Fargo & Company lifted their price objective on shares of Alumis from $49.00 to $51.00 and gave the stock an “overweight” rating in a research report on Friday, May 15th. Morgan Stanley reiterated an “overweight” rating and issued a $39.00 price objective on shares of Alumis in a report on Friday, May 15th. Finally, Guggenheim increased their price objective on shares of Alumis from $32.00 to $34.00 and gave the company a “buy” rating in a research report on Friday, May 15th. One research analyst has rated the stock with a Strong Buy rating, nine have given a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $40.30.

About Alumis

Our mission is to significantly improve the lives of patients by replacing broad immunosuppression with targeted therapies. Our name, Alumis, captures our mission to enlighten immunology, and is inspired by the words “allumer”-French for illuminate-and “immunis”-Latin for the immune system. We are a clinical stage biopharmaceutical company with an initial focus on developing our two Tyrosine Kinase 2 (TYK2) inhibitors: ESK-001, a second-generation inhibitor that we are developing to maximize target inhibition and optimize tolerability, and A-005, a central nervous system (CNS) penetrant molecule.